{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:42Z","timestamp":1788952362189,"version":"build-2803163510"},"reference-count":119,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Zambon S.p.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Cough is a common symptom associated with many mild and severe medical conditions such as acute and chronic respiratory disorders. However, it can also be linked to extrapulmonary pathologies such as gastroesophageal reflux. Whilst often beneficial in clearing secretions, a persistent dry cough can significantly impair quality of life and necessitate pharmacological intervention. Cloperastine, a non-opioid antitussive agent with central and peripheral mechanisms of action, is widely used in clinical practice. This narrative review critically examines the pharmacological properties, clinical efficacy and safety profile of cloperastine in the management of non-productive cough across adult and paediatric populations. In preclinical studies, cloperastine demonstrated antitussive efficacy 1.9 times greater than that of codeine, without narcotic effects. Moreover, cloperastine exhibits a quarter of the antihistaminic potency of diphenhydramine, does not impair mucociliary clearance and relaxes bronchial smooth muscle. Across more than 40 clinical studies, cloperastine was consistently effective in reducing cough frequency and intensity, with typical doses of 20\u201360 mg\/day (hydrochloride) or 10\u2013106 mg\/day (fendizoate) in adults, and 6\u2013106 mg\/day (fendizoate) or 5\u2013400 mg\/day (hydrochloride) in children, where dosing was fixed or adjusted for age or weight. The onset of action was observed as early as 20 minutes. It demonstrated superior or comparable efficacy to codeine, clobutinol, dextromethorphan, levodropropizine, butamirate and dihydrocodeine. In paediatric populations, it improved sleep quality and sputum quality. Cloperastine is a well-tolerated and effective antitussive with a rapid onset, favourable safety profile and low risk of central nervous system side-effects, supporting its role as a valuable therapeutic option for dry cough across all ages.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-cloperastine-in-paediatric-and-adult-cough-management-a-narrative-review<\/jats:p>","DOI":"10.7573\/dic.2025-10-6","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:42:23Z","timestamp":1779972143000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Cloperastine in paediatric and adult cough management: a historical narrative review"],"prefix":"10.7573","volume":"15","author":[{"given":"Ovidio","family":"Brignoli","sequence":"first","affiliation":[{"name":"General Practitioner Local Health Unit of Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6785-0753","authenticated-orcid":false,"given":"Cl\u00e1udia Henrique","family":"Da Costa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0198v2949","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade do Estado do Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7178-8187","authenticated-orcid":false,"given":"Jos\u00e9 R","family":"Jardim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02k5swt12","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zanasi","sequence":"additional","affiliation":[{"name":"Italian Association for Cough Study (AIST), Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tSato Y, Sugiyama Y, Ishida T, et al. The potential role of oxidative stress in modulating airway defensive reflexes. Antioxidants. 2025;14(5):568. https:\/\/doi.org\/10.3390\/antiox14050568","DOI":"10.3390\/antiox14050568"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tCatania MA, Cuzzocrea S. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther Clin Risk Manag. 2011;7:83\u201392. https:\/\/doi.org\/10.2147\/TCRM.S16643","DOI":"10.2147\/TCRM.S16643"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tTian PW, Wen FQ. Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease. J Transl Int Med. 2015;3:89\u201392. https:\/\/doi.org\/10.1515\/jtim-2015-0013","DOI":"10.1515\/jtim-2015-0013"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tKim WD. Lung mucus: a clinician\u2019s view. Eur Respir J. 1997;10(8):1914\u20131917. https:\/\/doi.org\/10.1183\/09031936.97.10081914","DOI":"10.1183\/09031936.97.10081914"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tIrwin RS, Boulet LP, Cloutier MM, et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest. 1998;114(2 Suppl.):133S\u2013181S. https:\/\/doi.org\/10.1378\/chest.114.2_supplement.133s","DOI":"10.1378\/chest.114.2_Supplement.133S"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tMorice AH, Fontana GA, Sovijarvi ARA, et al. The diagnosis and management of chronic cough. Eur Respir J. 2004;24(3):481\u2013492. https:\/\/doi.org\/10.1183\/09031936.04.00027804","DOI":"10.1183\/09031936.04.00027804"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tMorice AH, McGarvey L, Pavord I. Recommendations for the management of cough in adults. Thorax. 2006;61(Suppl. 1):i1\u2013i24. https:\/\/doi.org\/10.1136\/thx.2006.065144","DOI":"10.1136\/thx.2006.065144"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tZanasi A, Fontana AG, Mutolo D. Cough: pathophysiology, diagnosis and treatment 1st Ed. 2020 Edition. Springer; 2020.","DOI":"10.1007\/978-3-030-48571-9"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tBolser DC. Cough suppressant and pharmacologic protussive therapy. Chest. 2006;129(1 Suppl):238S\u2013249S. https:\/\/doi.org\/10.1378\/chest.129.1_suppl.238S","DOI":"10.1378\/chest.129.1_suppl.238S"},{"key":"ref9","unstructured":"10.\tWilliam Andrew Publishing. Pharmaceutical Manufacturing Encyclopedia. Elsevier; 2013:1103. https:\/\/books.google.it\/ books?id=_J2ti4EkYpkC&pg=PA1103&redir_esc=y#v=onepage&q&f=false. Accessed January 7, 2026."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tTakagi K, Fulcuda H, Fuije K, Matsui K, Sato M. Studies on antitussives. IV. Various drugs and \u03c9-(diphenilmetoxy) alkylamine compounds. J Pharm Soc Jap. 1961;81:261.","DOI":"10.1248\/yakushi1947.81.2_261"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tTakagi K, Yuizono T Kas\u00e9 Y. [On the site of antitussive action of 1-[2-(alpha-(p-chlorophenyl)-benzyloxy)-ethyl] piperidine (HT-11)]. Yakugaku Zasshi. 1967;87(8):907\u2013914.","DOI":"10.1248\/yakushi1947.87.8_907"},{"key":"ref12","unstructured":"13.\tSweetman SC, ed. Martindale: The complete drug reference. 35th ed. The Pharmaceutical Press; 2007:1401\u20131402."},{"key":"ref13","unstructured":"14.\tOlivieri D, Giacomelli P, Montella R, Illiano A, Gargano G, Pamparano F. Clinical study of a new antitussive: Cloperastine. Arch Monaldi. 1983;38:209\u2013218."},{"key":"ref14","unstructured":"15.\tOlivieri D, Del Donno M, Ferraro E. Effetto della cloperastina sulla clearance muco ciliare. Arch Monaldi. 1983;38: 219\u2013224."},{"key":"ref15","unstructured":"16.\tFabris C. Cloperastine in the treatment of cough. Eur Rev Med Pharmacol Sci. 1983;5:227\u2013230."},{"key":"ref16","unstructured":"17.\tDas A. Cloperastine hydrochloride CAS 14984 68 0 market share (%) by region (2021\u20132033). https:\/\/ www.cognitivemarketresearch.com\/cloperastine-hydrochloride-cas-14984-68-0-market-report. Accessed January 7, 2026."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tLun J, Zhao P, Jiang Z, Song Y, Guo X. Enantioselective LC-MS\/MS method for the determination of cloperastine enantiomers in rat plasma and its pharmacokinetic application. Chirality. 2020;32(8):1129\u20131138. https:\/\/doi.org\/10.1002\/ chir.23257","DOI":"10.1002\/chir.23257"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tDicpinigaitis PV, Morice AH, Birring SS, et al. Antitussive drugs \u2013 past, present, and future. Pharmacol Rev. 2014;66:468\u2013512. https:\/\/doi.org\/10.1124\/pr.111.005116","DOI":"10.1124\/pr.111.005116"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tMcLeod RL, Tulshian DB, Sadeh J. Where are the new cough treatments: a debriefing of recent clinical proof-of-concept trials with the NOP agonist SCH 486757. Pharmacology. 2011;88:50\u201354. https:\/\/doi.org\/10.1159\/ 000328782","DOI":"10.1159\/000328782"},{"key":"ref20","unstructured":"21.\tCamisasca E, Catenazzo G, Torri A. Cloperastine in chronic bronchopulmonary diseases. Eur Rev Med Pharmacol Sci. 1983;5:375\u2013378."},{"key":"ref21","unstructured":"22.\tNicrosini F, Pasotti C, Gandolfi P. Cloperastine in bronchopneumopathies associated with cardiocirculatory pathologies. A controlled clinical study [translation]. Basi Raz Ter. 1987;17:835\u2013838."},{"key":"ref22","unstructured":"23.\tNakazawa T, Tatani S, et al. Clinical Results of Hustazol, an antitussive\u2014a double-blind method with placebo [translation]. Report not dated. CSR on file Zambon."},{"key":"ref23","unstructured":"24.\tMorinaga T. Clinical trial of Hustazol. A new antitussive agent [translation]. Shinyaku to Rinsho. 1963;12:10\u201312."},{"key":"ref24","unstructured":"25.\tOldini C, Vecchi E. Double blind investigation of the antitussive effectiveness of cloperastine. Curr Ther Res. 1987;42:99\u2013105."},{"key":"ref25","unstructured":"26.\tZanon P, Mazzocchi P, Karitinos, Savio G, Oberhauser V. Double blind, placebo-controlled study of cloperastine, a new antitussive. [Italian]. Rassegna di Fisiopatologia, Clinica e Riabilitazione Cardiorespiratoria. 1985;7:45\u201349."},{"key":"ref26","unstructured":"27.\tNicrosini F, Marenzi V. Controlled clinical study: Z-15042 syrup. Data on file. Zyma S.p.A. Study conducted April\u2013June 1981."},{"key":"ref27","unstructured":"28.\tMaterazzi F. Studio clinico controllato Z-15042 compresse (Controlled clinical trial Z-15042 tablets). Data on file. Zyma S.p.A. Study conducted January\u2013May 1981."},{"key":"ref28","unstructured":"29.\tGhiringhelli G. Cloperastine (Z15042) in the treatment of cough in patients with exacerbated COPD: Controlled clinical study. Medical Praxis. 1981;2:290\u2013295."},{"key":"ref29","unstructured":"30.\tMargarino G, Scala M, Nocentini L. Cloperastine in the treatment of persistent chronic cough. A controlled clinical study. JAMA. 1998;10:3\u20137."},{"key":"ref30","unstructured":"31.\tThiekotter P. Cloperastine versus codeine: controlled clinical study in outpatients with cough of various origin [translation]. Progr Med Rome. 1987;43:279\u2013282."},{"key":"ref31","unstructured":"32.\tZ7193L02 _CSR: Open-label, multi-site, randomized, two-arm comparative study of efficacy and safety of the pharmaceutical products \u201cSeki (cloperastine) oral suspension 3.54 mg\/mL\u201d (Zambon S.p.A., Italy) and \u201cSinecod (butamirate) syrup 1.5 mg\/mL\u201d (GSK Consumer Healthcare S.A., Switzerland) in patients with dry nonproductive cough associated with acute upper respiratory. Report date: July 6, 2021. https:\/\/clinline.ru\/reestr-issledovatelej\/ podrobno-ob-issledovatele.html?id=8779"},{"key":"ref32","unstructured":"33.\tCicchetti M. Cloperastine syrup (Seki) in the treatment of cough in children. Italian. Aggiornamento Pediatrico. 1983;34:325\u2013350."},{"key":"ref33","unstructured":"34.\tSvitaylo O. Efficacy and tolerability of cloperastine fendizoate in the treatment of children and adolescents with cough caused by respiratory infections: effect on night-time cough and the quality of sleep of patients and parents. A randomised, double-blind, placebo controlled study. Int J Drugs Ther. 2005;22:35\u201343."},{"key":"ref34","unstructured":"35.\tSeidita F, Pamparana F. Nitossil: a new antitussive. A controlled paediatric study. [Italian]. Aggiornamento Pediatrico. 1983;34:363\u2013370."},{"key":"ref35","unstructured":"36.\tBarbato A, Monciotti C, Del Todesco Frisone G. Cloperastine (Nitossil) in the treatment of barking cough in children. Acta Paediatr. 1984;37:349\u2013357."},{"key":"ref36","unstructured":"37.\tGrasso U, Cinquepalmi P, Arancio R, Menichelli L, Sala M, Fiocchi A. Antitussive activity of a drop preparation of cloperastine: double blind placebo-controlled study. Rass Med Sper. 1988;35(1\u20132):1\u20136."},{"key":"ref37","unstructured":"38.\tScotti L, Borzani M. [Cloperastine fendizoate in the treatment of cough-producing diseases in pediatrics]. Minerva Pediatr. 1988;40(5):283\u2013286."},{"key":"ref38","unstructured":"39.\tFiocchi A, Arancio R, Giovannini M, et al. Treatment of pediatric respiratory illnesses with cloperastine drops [translation]. Riv Pediatr Prevent Soc. 1989;39(1):13\u201318."},{"key":"ref39","unstructured":"40.\tArima H. Clinical Effect of Hustazol syrup on acute inflammation in the upper respiratory tract of infants examined by use of a double blind method [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref40","unstructured":"41.\tTazaki K. Antitussive effects of Hustazol syrup \u2014 comparison of the effects of Hustazol syrup with those of dextromethorphan hydrobromide with the use of a double-blind trial design [translation]. Pediatr Clin. 1972;25:2\u20138."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"42.\tMontero P, Roger I, Esposito E, et al. Comparative analysis of classic and novel antitussives on cough suppression in guinea pigs. Pharmaceutics. 2025;17:1423. https:\/\/doi.org\/10.3390\/pharmaceutics17111423","DOI":"10.3390\/pharmaceutics17111423"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"43.\tTakagi K, Yuizono T, Kase Y. Investigation on the site of antitussive action of 1-[2]alfa-(p-chlorophenyl) benzyloxyethyl piperidine [HT-11]. J Pharm Soc Jap. 1987;87:907.","DOI":"10.1248\/yakushi1947.87.8_907"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"44.\tGregori-Puigjan\u00e9 E, Setola V, Hert J, et al. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A. 2012;109(28):11178\u201311183. https:\/\/doi.org\/10.1073\/pnas.1204524109","DOI":"10.1073\/pnas.1204524109"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tMorales-L\u00e1zaro SL, Gonz\u00e1lez-Ram\u00edrez R, Rosenbaum T. Molecular interplay between the sigma-1 receptor, steroids, and ion channels. Front Pharmacol. 2019;10:419. https:\/\/doi.org\/10.3389\/fphar.2019.00419","DOI":"10.3389\/fphar.2019.00419"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"46.\tBrown C, Fezoui M, Selig WM, et al. Antitussive activity of sigma-1 receptor agonists in the guinea-pig. Br J Pharmacol. 2004;141:233\u2013240. https:\/\/doi.org\/10.1038\/sj.bjp.0705605","DOI":"10.1038\/sj.bjp.0705605"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tShin SM, Wang F, Qiu C, et al. Sigma-1 receptor activity in primary sensory neurons is a critical driver of neuropathic pain. Gene Ther. 2022;29:1\u201315. https:\/\/doi.org\/10.1038\/s41434-020-0157-5","DOI":"10.1038\/s41434-020-0157-5"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tGordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459\u2013468. https:\/\/doi.org\/10.1038\/s41586-020-2286-9","DOI":"10.1038\/s41586-020-2286-9"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tVela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy? Front Pharmacol. 2020;11:582310. https:\/\/doi.org\/10.3389\/fphar.2020.582310","DOI":"10.3389\/fphar.2020.582310"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"50.\tJohnson CM, Cui N, Xing H, Wu Y, Jiang C. The antitussive cloperastine improves breathing abnormalities in a Rett Syndrome mouse model by blocking presynaptic GIRK channels and enhancing GABA release. Neuropharmacology. 2020;176:108214. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108214","DOI":"10.1016\/j.neuropharm.2020.108214"},{"key":"ref50","unstructured":"51.\tCanti G, Franco P, Nicolin A. Study on the pharmacological activity of cloperastine. Boll Chim Farm. 1983;122(8):384\u2013392."},{"key":"ref51","unstructured":"52.\tSvitaylo O. CLOP-I-02-00. The efficacy and tolerability of cloperastine fendizoate syrup in treating chronic cough of various etiologies in pediatric patients. A multicenter, unblinded, randomized, parallel group clinical study versus dihydrocodeine bitartrate plus benzoic acid, dextrometorphan bromide and levodropropizine. Data on file. Zambon S.p.A. Report date: March 2002."},{"key":"ref52","unstructured":"53.\tKoide G. Clinical use of Hustazol syrup in the treatment of infantile cough [translation]. Data on file. Zambon S.p.A. Study conducted December 1966\u2013March 1967."},{"key":"ref53","unstructured":"54.\tNicrosini F, Pasotti P. Sperimentazione clinica controllata sul preparato Hustazol (confetti, tavolette masticabili, sciroppo) della Ditta SIMES. Data on file. SIMES S.p.A. Report date: 1977."},{"key":"ref54","unstructured":"55.\tHomma M, Tsuchiya E, Ono H. Clinical experiences with Hustazol (HT-11). Med Consult New Remed. 1965;2(3):31\u201333."},{"key":"ref55","unstructured":"56.\tPubChem Cloperastine. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Cloperastine. Accessed August 29, 2025."},{"key":"ref56","unstructured":"57.\tDrugBank Cloperastine. https:\/\/go.drugbank.com\/drugs\/DB09002. Accessed August 29, 2025."},{"key":"ref57","unstructured":"58.\tThe Japanese Pharmacopeia\u201418th Edition (JP18). https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/ 0000066597.html. Accessed August 29, 2025."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tMohanraj K, Deshpande K, Pathak P, Joshi V, Barton S. A simple and cost-effective synthesis of sulfated \u03b2-cyclodextrin and its application as chiral mobile phase additive in the separation of cloperastine enantiomers. J Incl Phenom Macrocycl Chem. 2022;102(3):279\u2013293. https:\/\/doi.org\/10.1007\/s10847-021-01117-y","DOI":"10.1007\/s10847-021-01117-y"},{"key":"ref59","unstructured":"60.\tMarzo A, Parenti M. Pharmacokinetics of Cloperastine in volunteer human subjects. Istituto Simes report, Data on file. Zambon S.p.A. Report date: October 21, 1980."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tLi H, Zhang C, Wang J, Jiang Y, Fawcett JP, Gu J. Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2010;51(3):716\u2013722. https:\/\/doi.org\/10.1016\/j.jpba.2009.10.009","DOI":"10.1016\/j.jpba.2009.10.009"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tLuo HY, Long HZ, Zhou ZW, et al. Pharmacokinetics, bioequivalence and safety of cloperastine in Chinese healthy subjects under fasting and postprandial conditions. Drugs R D. 2022;22(4):311\u2013320. https:\/\/doi.org\/10.1007\/ s40268-022-00406-2","DOI":"10.1007\/s40268-022-00406-2"},{"key":"ref62","unstructured":"63.\tKato Y, Furuta T. Absorption, distribution, excretion and metabolism of 14C-cloperastine syrup in rats [abstract]. Pharmacometrics. 1971;5:735."},{"key":"ref63","unstructured":"64.\tSugimoto J, Tamefuji K, Okuura T, Inoue Y. Absorption and excretion of Hustazol syrup in man. data on file. Yoshitomi pharmaceutical industries Ltd."},{"key":"ref64","unstructured":"65.\tMargarino G. Efficacia e tollerabilit\u00e0 della clopetrastina fendizoato nel trattamento della tosse cronica di varia eziologia. L\u2019internista. 2002;10:153\u2013159."},{"key":"ref65","unstructured":"66.\tAllegra L, Bossi R. Clinical trials with the new antitussive levodropropizine in adult bronchitic patients. Arzneimittelforschung. 1988;38:1163\u20131166."},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"67.\tAliprandi P, Cima L, Carrara M. Therapeutic use of levocloperastine as an antitussive agent. Clin Drug Investig. 2002;22:209\u2013220. https:\/\/doi.org\/10.2165\/00044011-200222040-00001","DOI":"10.2165\/00044011-200222040-00001"},{"key":"ref67","unstructured":"68.\tAliprandi P, Castelli C, Bernorio S, Dell\u2019Abate E, Carrara M. Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents. Drugs Exp Clin Res. 2004;30: 133\u2013141."},{"key":"ref68","unstructured":"69.\tSechi F. Evaluation of the activity and tolerability of L-Clofend Magis in the symptomatic treatment of cough: a controlled clinical study vs cloperastine. Data on file. Aesculapius Farmaceutici SpA, Magis Farmaceutici SpA. Report year 1992."},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"70.\tMolassiotis A, Smith JA, Mazzone P, Blackhall F, Irwin RS, CHEST Expert Cough Panel. Symptomatic treatment of cough among adult patients with lung cancer: CHEST guideline and expert panel report. Chest. 2017;151(4):861\u2013874. https:\/\/doi.org\/10.1016\/j.chest.2016.12.028","DOI":"10.1016\/j.chest.2016.12.028"},{"key":"ref70","unstructured":"71.\tYoshikawa H. Clinical experience with Hustazol [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref71","unstructured":"72.\tSone T. Clinical Experiences with Hustazol [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref72","unstructured":"73.\tSugita K. Clinical Experiences with Hustazol [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref73","unstructured":"74.\tYamamoto Y, Matsushima Y, Yamaguchi T, et al. Clinical experience with Hustazol. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref74","unstructured":"75.\tPurello D\u00b4Ambrosio F, Pant\u00f2 E, Lombardo G, Marotta G, Tigano V. Cloperastine in the treatment of cough in patients with recrudescent chronic obstructive bronchopulmonary disease [translation]. Rass Med Int. 1984;5(5):539\u2013543."},{"key":"ref75","unstructured":"76.\tTorri A, Melloni R, Camisasca E, et al. La tosse in reparto di medicina generale . Il ruolo svolto da un nuovo antitosse nella pratica clinica quotidiana [translation]. Data on file. Zambon S.p.A."},{"key":"ref76","unstructured":"77.\tHigaki H. Clinical experience with H-11 (Hustazol). J New Remed Clin. 1965;14(5):52\u201356."},{"key":"ref77","unstructured":"78.\tWatanabe T. Clinical experience with Hustazol in cough symptoms of TB-patients [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref78","unstructured":"79.\tNemoto G, Mononobe N. Clinical expereiences with Hustazol \u2013 in post-operative cases and in the diseases of the lungs [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref79","unstructured":"80.\tTazaki K, Kanemitsu H. Clinical effects of Hustazol syrup on cough in infants [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref80","unstructured":"81.\tNakamura T, Hamashima E, Hayashi I. Clinical results of Hustazol syrup therapy in infants [translation]. Report not dated. Data on file. Zambon S.p.A."},{"key":"ref81","unstructured":"82.\tDel Ponte G, Bonollo L, Martini A. The use of dihydrocodeine in the treatment of pertussis. Comparative clinical study versus cloperastine [translation]. iorn Ital Ric Clin Ter. 1988;9:165\u2013168."},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"83.\tDe Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A. An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome. Cough. 2012;8(1):1. https:\/\/doi.org\/10.1186\/ 1745-9974-8-1","DOI":"10.1186\/1745-9974-8-1"},{"key":"ref83","unstructured":"84.\tTakagi S, Furuyama M. Clinical evaluation of Hustazol in the treatment of coughs in pediatric field. J Clin Pediatr. 1966;14:5."},{"key":"ref84","unstructured":"85.\tMiyako M, Sugimoto M, Lioka T. Clinical experience with antitussive, Hustazol. J New Rem Clin. 1967;16(7):819\u2013825."},{"key":"ref85","unstructured":"86.\tBruno F, Gobbato D. Clinical trial on the medicinal producty Hustazol [translation]. Sperimentazione clinica sul prodotto Hustazol. Data on file. Simes S.p.A. Report date March 23, 1978."},{"key":"ref86","unstructured":"87.\tGiordano C. Report on the clinical trial concerning the preparation Z-15042 syrup. Data on file. Zyma S.p.A. Study conducted January\u2013March 1981."},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"88.\tPaul IM, Yoder KE, Crowell KR, et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics. 2004;114(1):e85-90. https:\/\/doi.org\/ 10.1542\/peds.114.1.e85","DOI":"10.1542\/peds.114.1.e85"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"89.\tChang AB, Peake J, McElrea MS. Anti-histamines for prolonged non-specific cough in children. Cochrane Database Syst Rev. 2008;2008(2):CD005604. https:\/\/doi.org\/10.1002\/14651858.CD005604.pub3","DOI":"10.1002\/14651858.CD005604.pub3"},{"key":"ref89","unstructured":"90.\tSmith SM, Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2008;(1):CD001831. https:\/\/doi.org\/10.1002\/ 14651858.CD001831.pub3"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"91.\tChang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev. 2007;(4):CD006088. https:\/\/doi.org\/10.1002\/14651858.CD006088.pub2","DOI":"10.1002\/14651858.CD006088.pub2"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"92.\tGordillo A, Mart\u00ednez S\u00e1nchez L, Pretel Echaburu C, Trenchs Sainz de la Maza V, Gotzens Bersch J, Luaces Cubells C. Unintentional poisoning by cough and cold medications: drugs with little usefulness and potential toxicity. Anal Pediatria. 2022;97:326\u2013332. https:\/\/doi.org\/10.1016\/j.anpede.2022.09.005","DOI":"10.1016\/j.anpede.2022.09.005"},{"key":"ref92","unstructured":"93.\tCloperastine SmPC. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=cloperastina&spellingCorrection=true. Accessed September 1, 2025."},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"94.\tTakahara A, Fujiwara K, Ohtsuki A, Oka T, Namekata I, Tanaka H. Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs. J Pharmacol Sci. 2012;120(3):165\u2013175. https:\/\/doi.org\/10.1254\/jphs.12117fp","DOI":"10.1254\/jphs.12117FP"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"95.\tSekul EA, Moak JP, Schultz RJ, Glaze DG, Dunn JK, Percy AK. Electrocardiographic findings in Rett syndrome: an explanation for sudden death? J Pediatr. 1994;125(1):80\u201382. https:\/\/doi.org\/10.1016\/s0022-3476(94)70128-8","DOI":"10.1016\/S0022-3476(94)70128-8"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"96.\tLinazasoro G, Garmendia MT, Lizaso X. Acute dystonia in a young schizophrenic patient associated with ingestion of a cloperastine containing cough syrup. Parkinsonism Relat Disord. 2000;6(1):57\u201358. https:\/\/doi.org\/10.1016\/ s1353-8020(99)00042-5","DOI":"10.1016\/S1353-8020(99)00042-5"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"97.\tSerrano M, Sanz-Cuesta M, Villaronga M, Frontado Hayek L, Perez-Due\u00f1as B. Cloperastine-based cough syrup and acute dystonic reactions. Dev Med Child Neurol. 2012;54(3):287. https:\/\/doi.org\/10.1111\/j.1469- 8749.2011.04105.x","DOI":"10.1111\/j.1469-8749.2011.04105.x"},{"key":"ref97","unstructured":"98.\tDihydrocodeine SmPC. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=PARACODINA%20 (MEDICINALE)&exact=true. Accessed September 1, 2025."},{"key":"ref98","unstructured":"99.\tButamirate SmPC. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=BUTAMIRATO%20CITRATO%20(PRINCIPIO%20 ATTIVO)&exact=true. Accessed September 1, 2025."},{"key":"ref99","unstructured":"100.\tLevodropropizine SmPC. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=LEVODROPROPIZINA%20(PRINCIPIO%20 ATTIVO)&exact=true. Accessed September 1, 2025."},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"101.\tGraudins A, Fern RP. Acute dystonia in a child associated with therapeutic ingestion of a dextromethorphan containing cough and cold syrup. J Toxicol Clin Toxicol. 1996;34(3):351\u2013352. https:\/\/doi.org\/ 10.3109\/15563659609013802","DOI":"10.3109\/15563659609013802"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"102.\tKnowles SR, Weber E. Dextromethorphan anaphylaxis. J Allergy Clin Immunol. 1998;102(2):316\u2013317. https:\/\/doi.org\/ 10.1016\/s0091-6749(98)70101-0","DOI":"10.1016\/S0091-6749(98)70101-0"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"103.\tCook J, Stith M, Sahn EE. Bullous mastocytosis in an infant associated with the use of a nonprescription cough suppressant. Pediatr Dermatol. 1996;13(5):410\u2013414. https:\/\/doi.org\/10.1111\/j.1525-1470.1996.tb00712.x","DOI":"10.1111\/j.1525-1470.1996.tb00712.x"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"104.\tMcCarthy JP. Some less familiar drugs of abuse. Med J Aust. 1971;2(21):1078\u20131081. https:\/\/doi.org\/ 10.5694\/j.1326-5377.1971.tb92714.x","DOI":"10.5694\/j.1326-5377.1971.tb92714.x"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"105.\tHapangama A, Kuruppuarachchi K a. LA. Dextromethorphan abuse. Ceylon Med J. 2008;53(3):109\u2013110. https:\/\/doi.org\/10.4038\/cmj.v53i3.256","DOI":"10.4038\/cmj.v53i3.256"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"106.\tKrystal A, Richalson E, Roth T. Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev. 2013;17(4):263\u2013272. https:\/\/doi.org\/10.1016\/j.smrv.2012.08.001","DOI":"10.1016\/j.smrv.2012.08.001"},{"key":"ref106","unstructured":"107.\tDextromethorphan SmPC. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=DESTROMETORFANO%20 (PRINCIPIO%20ATTIVO)&exact=true. Accessed September 1, 2025."},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"108.\tOmoto N, Kanzawa Y, Ishimaru N, Kinami S. Serotonin syndrome after an overdose of over-the-counter medicine containing dextromethorphan. J Gen Fam Med. 2021;23(1):38\u201340. https:\/\/doi.org\/10.1002\/jgf2.469","DOI":"10.1002\/jgf2.469"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"109.\tSchwartz AR, Pizon AF, Brooks DE. Dextromethorphan-induced serotonin syndrome. Clin Toxicol. 2008;46(8):771\u2013773. https:\/\/doi.org\/10.1080\/15563650701668625","DOI":"10.1080\/15563650701668625"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"110.\tBellocq C, Wilders R, Schott JJ, et al. A common antitussive drug, clobutinol, precipitates the long QT syndrome 2. Mol Pharmacol. 2004;66(5):1093\u20131102. https:\/\/doi.org\/10.1124\/mol.104.001065","DOI":"10.1124\/mol.104.001065"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"111.\tShah RR. Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol. 2013;75(2):347\u2013358. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04415.x","DOI":"10.1111\/j.1365-2125.2012.04415.x"},{"key":"ref111","unstructured":"112.\tEMA. Questions and answers on the recommendations to withdraw the marketing authorisations for clobutinol-containing medicines. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/questions-and-answers-recommendation-withdraw-marketing-authorisations-clobutinol-containing-medicines_en.pdf. Accessed July 17, 2025."},{"key":"ref112","unstructured":"113.\tMedicines and Healthcare products Regulatory Agency. Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure. https:\/\/www.gov.uk\/drug-safety-update\/pholcodine-containing-cough-and-cold-medicines-withdrawal-from-uk-market-as-a-precautionary-measure. Accessed July 17, 2025."},{"key":"ref113","unstructured":"114.\tEMA. EMA recommends withdrawal of pholcodine medicines from EU market. https:\/\/www.ema.europa.eu\/en\/ news\/ema-recommends-withdrawal-pholcodine-medicines-eu-market. Accessed July 17, 2025."},{"key":"ref114","doi-asserted-by":"crossref","unstructured":"115.\tBriars LA. The latest update on over-the-counter cough and cold product use in children. J Pediatr Pharmacol Ther. 2009;14(3):127\u2013131. https:\/\/doi.org\/10.5863\/1551-6776-14.3.127","DOI":"10.5863\/1551-6776-14.3.127"},{"key":"ref115","doi-asserted-by":"crossref","unstructured":"116.\tCommittee on Drugs. Use of codeine- and dextromethorphan-containing cough remedies in children. American Academy of Pediatrics. Committee on Drugs. Pediatrics. 1997;99(6):918\u2013920. https:\/\/doi.org\/10.1542\/ peds.99.6.918","DOI":"10.1542\/peds.99.6.918"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"117.\tChang AB, Oppenheimer JJ, Irwin RS; CHEST Expert Cough Panel. Managing Chronic Cough as a Symptom in Children and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2020;158:303\u2013329. https:\/\/doi.org\/10.1016\/j.chest.2020.01.042","DOI":"10.1016\/j.chest.2020.03.065"},{"key":"ref117","doi-asserted-by":"crossref","unstructured":"118.\tWark PA, Marchant JM. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia. Med J Aust. 2024;220:492. https:\/\/doi.org\/10.5694\/mja2.52277","DOI":"10.5694\/mja2.52277"},{"key":"ref118","doi-asserted-by":"crossref","unstructured":"119.\tMorice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. https:\/\/doi.org\/10.1183\/13993003.01136-2019","DOI":"10.1183\/13993003.01136-2019"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/05\/dic.2025-10-6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:25:43Z","timestamp":1788949543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/cloperastine-in-paediatric-and-adult-cough-management-a-historical-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":119,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-10-6","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"dic.2025-10-6"}}